Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Thymosin Beta-4? Benefits, Research & Safety
A 43-amino acid peptide naturally present in all cells, fundamental to tissue repair, cell migration, and regeneration processes throughout the body.
Also known as:
Tβ4
TB4
TMSB4X
UK summary: Not a licensed UK medicine. The full-length parent protein of TB-500; investigated in some early human cardiac and wound-healing trials. Treated by WADA as prohibited under the growth-factors category.
Quick Facts
Category
Healing & Recovery
Half-Life
Relatively short plasma half-life; effects may persist longer due to intracellular mechanisms
UK Status
Not licensed for human therapeutic use. Research compound.
EU Status
Orphan drug designation for some indications. Not generally approved.
Overview
Thymosin Beta-4 (Tβ4) is a 43-amino acid, water-soluble peptide that is expressed in virtually all cell types throughout the human body. It is one of the most abundant intracellular proteins, with particularly high concentrations in blood platelets, wound fluid, and developing tissues.
Originally isolated from the thymus gland, hence its name, Thymosin Beta-4 has since been found to play fundamental roles far beyond immune function. Its primary biological role is as an actin-sequestering protein, binding to monomeric actin (G-actin) and regulating the dynamics of the cellular cytoskeleton—essential for cell movement and division.
The discovery of Thymosin Beta-4's profound effects on wound healing and tissue regeneration has generated significant scientific and clinical interest. The peptide promotes cell migration, angiogenesis, and the differentiation of stem cells, making it a focus of regenerative medicine research.
Clinical trials have investigated Thymosin Beta-4 for wound healing, cardiac repair following myocardial infarction, and treatment of dry eye syndrome. While results have been promising, regulatory approval for most applications remains pending.
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4 and is often used in research settings as a more accessible alternative to the full molecule.
Evidence standards summary
Thymosin Beta-4 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.
Not a licensed UK medicine. The full-length parent protein of TB-500; investigated in some early human cardiac and wound-healing trials. Treated by WADA as prohibited under the growth-factors category.
02Human evidence grade
DAnimal/cell evidence onlyStrength of evidence from published human trials.
03Preclinical evidence grade
BModerate human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed for human therapeutic use. Research compound.
- EU: Orphan drug designation for some indications. Not generally approved.
- Notes: Thymosin Beta-4 has received orphan drug designation for certain conditions but remains largely in clinical development. RegeneRx has advanced several Tβ4-based products through clinical trials.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Faster healing of any injury.
- Heart-attack recovery accelerator.
- Safe for daily long-term injection.
07Common internet claims
- Marketed alongside TB-500 as the 'full' thymosin beta-4 product.
- Sold by online retailers as research-only injectable.
- Promoted by athletes despite WADA prohibition.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Repairs cardiac tissue after heart attack” | C | Limited | High | Early-phase human cardiac trials investigated Tβ4 for myocardial repair; outcomes data did not produce a licensed product. |
| “Heals injuries faster than TB-500” | E | No | High | No head-to-head human trials of full Tβ4 vs the commercial TB-500 fragment exist. |
| “Safe for long-term use” | E | No | High | Long-term human safety is not established. |
| “Available from research suppliers — same molecule as clinic-grade” | E | No | High | Grey-market protein supply lacks identity / purity verification. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Limited human safety data outside small Phase 2 cardiac trials.
- WADA S2 prohibited.
- Injection-site reactions.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Prohibited in sportWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not licensed for human therapeutic use. Research compound.
14EU legal position
Orphan drug designation for some indications. Not generally approved.
15What this page cannot tell you
- Whether a UK-purchased vial contains TB4 at the labelled concentration.
- Long-term oncologic risk from sustained TB4 elevation.
16Last reviewed
17Citation quality score
CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Phase 3 trials for any indication absent.
- Long-term healthy-adult safety unstudied.
19Safer alternatives / established care pathways
- NHS physiotherapy + sports-medicine pathway for tissue injury.
- NHS cardiology pathway for cardiac concerns.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Thymosin Beta-4 a licensed UK medicine?
- What human evidence exists beyond the early-phase cardiac trials?
- If I'm an athlete, what is the WADA position on Tβ4 and TB-500?
- What licensed treatments exist for my underlying injury or cardiac concern?
Discovery & History
Thymosin Beta-4 was first isolated from the thymus gland in 1966 by Allan Goldstein at the Albert Einstein College of Medicine. The thymus, known for its role in T-cell maturation and immune function, was the source of numerous "thymosin" peptides believed to have immunological activity.
Initial research in the 1970s and 1980s focused on potential immunological applications. However, the discovery that Thymosin Beta-4 was present in virtually all cell types—not just immune tissues—suggested broader biological functions.
The breakthrough came with the identification of Thymosin Beta-4 as a major actin-sequestering protein in the early 1990s. This finding revealed its fundamental role in regulating cell structure and movement. Researchers found that Tβ4 binds to G-actin with high affinity, preventing premature polymerisation and allowing controlled cytoskeletal dynamics.
Subsequent research in the late 1990s and 2000s demonstrated Thymosin Beta-4's remarkable wound healing properties. Studies showed accelerated wound closure, enhanced angiogenesis, and reduced inflammation in various injury models.
The peptide entered clinical trials for several indications including wound healing, cardiac repair, and dry eye disease. RegeneRx Biopharmaceuticals developed Tβ4-based therapies including RGN-259 for ophthalmic use.
Mechanism of Action
Thymosin Beta-4 exerts its biological effects through multiple interconnected mechanisms:
**Actin Binding and Cell Motility**
Tβ4 is the primary actin-sequestering protein in cells, binding to G-actin and regulating the pool of actin available for polymerisation into filaments. By controlling actin dynamics, Tβ4 enables cells to migrate efficiently—a critical process in wound healing and tissue repair.
**Cell Migration Promotion**
Through its effects on the cytoskeleton, Tβ4 enhances the migration of various cell types including endothelial cells, keratinocytes, and stem cells to sites of injury. This recruitment of reparative cells is essential for tissue regeneration.
**Angiogenesis Stimulation**
Thymosin Beta-4 promotes the formation of new blood vessels by stimulating endothelial cell migration, survival, and tube formation. Improved vascularisation enhances nutrient delivery and supports tissue repair.
**Anti-Inflammatory Effects**
Tβ4 modulates inflammatory responses, reducing the production of pro-inflammatory cytokines and promoting resolution of inflammation. This creates an environment more conducive to healing rather than scarring.
**Stem Cell Activation**
Research demonstrates that Tβ4 can activate resident stem cells and progenitor cells, promoting their differentiation toward tissue-specific cell types. This is particularly relevant in cardiac regeneration research.
**Anti-Apoptotic Activity**
Thymosin Beta-4 has been shown to promote cell survival by inhibiting apoptotic pathways, protecting cells from death following injury or ischemia.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Accelerated wound healing with improved tissue quality
- 2Enhanced cardiac repair and regeneration following injury
- 3Improved angiogenesis and blood vessel formation
- 4Reduced inflammation and scarring
- 5Potential benefits for dry eye syndrome
- 6Possible neuroprotective effects in brain injury
- 7Support for hair follicle regeneration
- 8Enhanced stem cell activation and tissue regeneration
Claim vs Evidence
How popular claims about Thymosin Beta-4 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Repairs cardiac tissue after heart attack” | C | Limited | High | Early-phase human cardiac trials investigated Tβ4 for myocardial repair; outcomes data did not produce a licensed product. |
| “Heals injuries faster than TB-500” | E | No | High | No head-to-head human trials of full Tβ4 vs the commercial TB-500 fragment exist. |
| “Safe for long-term use” | E | No | High | Long-term human safety is not established. |
| “Available from research suppliers — same molecule as clinic-grade” | E | No | High | Grey-market protein supply lacks identity / purity verification. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Variable depending on application and formulation; clinical trials have used various dosing regimens |
| Frequency | Depends on indication and delivery method |
| Duration | Variable by application |
| Notes | Thymosin Beta-4 has been studied in clinical trials for specific indications. Protocols vary significantly. Any use should be under medical supervision and preferably within clinical research frameworks. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Intramuscular injection
- Topical application (eye drops for dry eye)
- Intravenous administration (certain clinical settings)
| Half-Life | Stability |
|---|---|
| Relatively short plasma half-life; effects may persist longer due to intracellular mechanisms | Stable when properly stored; lyophilised forms preferred for long-term storage |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions
- Temporary fatigue or flu-like symptoms
- Mild headache in some cases
Rare Risks & Concerns
- Unknown long-term effects from exogenous administration
- Theoretical concerns regarding tumour promotion
- Possible cardiovascular effects
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Certain cardiovascular conditions
- Children (limited safety data)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human therapeutic use. Research compound.
🇪🇺 European Union
Orphan drug designation for some indications. Not generally approved.
Thymosin Beta-4 has received orphan drug designation for certain conditions but remains largely in clinical development. RegeneRx has advanced several Tβ4-based products through clinical trials.
Clinical Studies Summary
Thymosin β4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell Migration and Survival
Demonstrated Tβ4's cardioprotective mechanisms and potential for cardiac regeneration.
Nature. 2004;432(7016):466-72View on PubMed
Phase 2 Clinical Trial of RGN-259 for Dry Eye
Clinical investigation of Tβ4-based eye drops for treatment of dry eye syndrome showing promising results.
ClinicalTrials.govView on PubMed
Looking for Thymosin Beta-4?
Source research-grade Thymosin Beta-4 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Thymosin Beta-4
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Thymosin Beta-4 a licensed UK medicine?
- What human evidence exists beyond the early-phase cardiac trials?
- If I'm an athlete, what is the WADA position on Tβ4 and TB-500?
- What licensed treatments exist for my underlying injury or cardiac concern?
UK regulatory & safety context
Peptide Comparisons
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreTB-500
A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.
Learn moreGHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn more